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survival (DFS) were used as main outcomes in these
transplantations.
Results: Thirteen patients including 7 boys and 6 girls with
mean age 5.33 years (range: 0.25-11) were detected through
the data registry bank. The mean donors' age was 61.77 years
(range: 45-75) and mean age difference was 56.44 years
(range: 36.5-73) [Table 1]. Regarding GVHD occurrence, 10
patients did experience acute GVHD [Table 1]. With median
follow-up of 16 months OS and DFS were 83% and 69%
respectively.
Conclusion: Although searching the extended family for
HLA-matched donors especially among grandparents seems
very uncommon, this can increase the chance of well-toler-
ated and success transplantation especially in regions where
consanguinity is common.
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Haploidentical donor is often the only source of graft for
most patients in developing countries due to lack of suitably
matched donors from international registries and the
prohibitive cost involved in the procurement process. We
conducted a pilot study with posttransplant cyclophospha-
mide and haploidentical PBSC graft. The donors selected
were either mother or NIMA mismatched siblings irre-
spective of NK cell alloreactivity. The conditioning protocol
was developed based on Johns Hopkins regimen of Fludar-
abine and low-dose Cyclophosphamide pre-transplant with
escalating doseMelphalan 70-140mg/m2 replacing 2 Gy TBI.
Post-transplant Cyclophosphamide was administered 72hrs
after infusion of the graft at 50 mg/kg twice at 24 hrs interval
followed by Cyclosporine and MMF.
8 patients (median age-16, 5-43) underwent Haplo-HCT; 5
patients with refractory AML had a median BM blast count of
50% (20-80%) having failed at least two lines of treatment.
Two patients had severe aplastic anemia and one had thal-
assemia. The ones with AML received high dose AraC and
mitoxantrone from day-14 to -12. The conditioning was
tolerated without any major non-hematological toxicity. The
median CD34 was 7.06 x 106/kg (range 5.05-11.06) and CD3
was 36 x 107/kg (range 8-79).
All patients engrafted with neutrophils > 500/ml on day +14
(range12-17) and platelet count > 20,000/ml on day +15
(range 9-38) with > 95% donor chimerism on day +30 with
morphological CR. None of the patients with leukemia
developed de-novo GVHD. Three relapsed between days
100-150 and two of them achieved a CR following a second
transplant from the same donor. Two patients in CR died of
multi-drug resistant gram-negative bacterial sepsis. All three
patients with non-malignant disease developed unexpected
alloreactivity. One patient with SAA developed severerefractory HLH on day +21 and the other a periengraftment
idiopathic pneumonitis. Both succumbed to their complica-
tions. Another patient with thalassemia developed severe
HLH on day 60 related to EBV, whilst on treatment for grade 3
acute GVHD. In multiply treated advanced leukemia, the
introduction of the PBSC graft without any immunosup-
pression for 72 hours probably allowed a strong GVL effect
and post-transplant cyclophosphamide was successful in
abrogating clinically signiﬁcant GVHD. In sharp contrast, all
the three patients with non-malignant disease experienced
early and unexpected alloreactivity with the same protocol.
We speculate that the lack of previous cytotoxic therapy
might have left them vulnerable to such alloreactivity
mediated by residual host APCs.
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Early relapse (within 120 days) of high risk acute leukemia
after any form of allogeneic HCT, augers a poor outcome. We
report our experience with 4 such patients who relapsed
within 120 days of undergoing a haploidentical PBSCTwith or
without posttransplant cyclophosphamide. None developed
GVHD even with prophylactic DLI. Three had relapsed
refractory AML at the time of the ﬁrst haploidentical HCT and
one was transplanted for high risk ALL. The marrow blast
count at the time of second transplant was 20-80%. The
patients were conditioned with Fludarabine or Cladribine
withmelphalan (70mg/m2) ororal busulfan (4mg/kg) anddid
not receive any GVHD prophylaxis. Cryopreserved PBSC graft
was infused with CD34+ cells varying between 2-3 x 106/kg.
All the patients engrafted within 14 days and all developed
grade 2-3 acute GVHD by day 10. GVHD was treated with
steroids and etanercept along with tacrolimus andMMF. One
patient succumbed early to multidrug resistant Klebsiella
sepsis on day 15. The BM on day 30 in the other 3 patients
showed 100 % donor chimerismwith MRD levels of less than
0.1% on ﬂow cytometry. At a short follow up of 90 days from
the second haploidentical HCT, two out of three patients are
alive in CR with tapering immunosuppresion and the other
was lost to follow up after 50 days. Our data shows that
a haploidentical graft can induce a potent enough GVL effect
to induce remission even in refractory leukemia. These ﬁnd-
ings highlight the fact that even if a patient with refractory
leukemia relapses early after an allogeneic HCT without
developing GVHD, they deserve a second graft from the same
donor with minimally toxic conditioning with the purpose of
inducing a GVHD/GVL effect.
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